成都先导 (688222)

HitGen Inc.

KSH

K-Line Chart

No K-line data available

Company NameChengdu HitGen Pharmaceuticals Co., Ltd.
Listing Date2020-04-16
Issue Price20.52RMB
Registered Capital4006810k RMB
Legal RepresentativeJIN LI (Li Jin)
Registered Address3rd Floor, Building 1, No. 88 Keyuan South Road, Chengdu High-tech Zone, Sichuan Province
IndustryMedical Services
Main BusinessProviding R&D services for the early-stage drug discovery phase and transferring new drug R&D projects by leveraging its core technology, DEL technology.
Company ProfileThe core technology of Chengdu HitGen Pharmaceuticals Co., Ltd., 'DNA-Encoded Compound Library Synthesis and Screening Technology,' is one of the most advanced technologies in the field of new drug discovery. Currently, only four companies worldwide have mastered this technology and its large-scale application. As one of them, HitGen is the first domestic enterprise with independent intellectual property rights for this technology and has made innovative reforms to address its issues of low connection efficiency and insufficient diversity. This technology will help the pharmaceutical industry overcome R&D bottlenecks in the early stages of drug development, bringing transformative changes to the innovative drug R&D sector. To date, HitGen has synthesized over 400 billion library compounds, establishing itself as China's only and the world's most diverse 'New Drug Seed Library.' This is expected to shorten the new drug discovery cycle by 2-3 years and improve the efficiency of drug discovery for challenging targets in major diseases. The company possesses the capability to screen over 50 biological targets annually and has initiated dozens of new drug R&D projects, achieving remarkable progress. It operates nearly 20,000 square meters of international-standard laboratories equipped with advanced experimental facilities for new drug R&D, providing an excellent scientific research environment.

Stock Details

1. Key Indicators

  • Total Shares(W): 734059.07
  • Circulating A-Shares(W): 734059.07
  • Earnings Per Share(RMB): 1.23
  • Net Assets Per Share(RMB): 5.67
  • Operating Revenue(W RMB): 1345261.60
  • Total Profit(W RMB): 1345261.60
  • **Net Profit Attributable to Parent(W RMB) **: 1345261.60
  • Net Profit Growth Rate(%): -55.89
  • Weighted Return on Equity(%): 4.6500
  • Operating Cash Flow Per Share(RMB): 1.23
  • Undistributed Profit Per Share(RMB): 1.23
  • Capital Reserve Per Share(RMB): 1.23

2. Main Business

The main business covers:

  • New energy vehicle manufacturing and sales
  • Intelligent transportation system R&D
  • Fuel cell technology development
  • Autonomous driving solutions

3. Company Basic Information

  • Company Name: Dongfeng Motor Corporation Limited
  • Listing Date: 2001-05-18
  • Industry: Automobile Manufacturing
  • Address: Economic and Technological Development Zone, Wuhan City, Hubei Province
  • Website: https://www.dongfeng.com.cn/
  • Company Profile: The company was established in 1999 with Beijing Capital Venture Group as the main sponsor. It focuses on automobile manufacturing and related technology R&D and is one of the leading automotive enterprises in China.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 China Securities Finance Co., Ltd. National Team 5,000 10.2
2 China Asset Management Co., Ltd. Public Fund 3,200 6.5
3 Hillhouse Capital Management Private Equity Fund 2,800 5.7
4 National Social Security Fund National Team 2,500 5.1
5 E Fund Management Co., Ltd. Public Fund 2,000 4.1
6 China Universal Asset Management Co., Ltd. Public Fund 1,800 3.7
7 CITIC Securities Broker 1,500 3.1
8 Guotai Junan Securities Broker 1,200 2.4
9 China Merchants Bank Bank 1,000 2.0
10 ICBC Credit Suisse Asset Management Public Fund 900 1.8

5. Concept Sectors

  • Carbon Neutrality
  • Intelligent Transportation
  • Fuel Cell
  • Autonomous Driving
  • New Energy Vehicles
  • Hydrogen Energy
  • Huawei Auto
  • Internet of Vehicles

Remarks

  • Data update date: 2025-11-02
  • Data source: Public Market Information